(PASG) Passage Bio, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PASG) Passage Bio, Inc. Complete Analysis Pack
Passage Bio Business Model Canvas: Strategy, Partnerships, Value
Unlock the full strategic blueprint behind Passage Bio, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, builds partnerships, and navigates the biotech landscape. Ideal for investors, analysts, and strategists who want deeper insight—download the full version to see every building block.
Partnerships
Trustees of the University of Pennsylvania Gene Therapy Program collaboration
Passage Bio’s collaboration with the Trustees of the University of Pennsylvania Gene Therapy Program is a core external partnership, giving it access to top-tier vector science, translational research, and gene therapy expertise. This academic link has been central to building Passage Bio’s AAV platform and advancing its rare-disease pipeline.
Catalent Maryland development services agreement
Passage Bio, Inc. relies on its development services and clinical supply agreement with Catalent Maryland, Inc. to make and deliver clinical AAV material, a critical step for advancing its investigational gene therapies. This kind of outside manufacturing support helps Passage Bio keep trial supply moving without building full in-house production capacity.
Rare-disease clinical investigators
Passage Bio, Inc. relies on rare-disease clinical investigators, especially neurologists and geneticists, to run ultra-rare studies where patient pools are often measured in only dozens or low hundreds. These sites enroll patients and collect the safety and efficacy data that drive every clinical readout, making them core to Passage Bio, Inc.'s development path.
Academic medical centers
Academic medical centers are Passage Bio, Inc.'s core trial partners for rare CNS gene therapy, because they have the neurologists, imaging, genetic testing, and infusion teams these programs need. The U.S. NIH backs 58 Clinical and Translational Science Award hubs, which helps support biomarker work, natural-history studies, and long follow-up for small patient groups.
- Rare CNS trials need specialist care.
- Academic centers enable biomarker studies.
- They support long-term patient follow-up.
Patient and disease communities
Patient and disease communities are key for Passage Bio, Inc. because rare-disease groups help find eligible patients, spread trial awareness, and shape protocol choices like endpoints and visit burden. That matters most in ultra-rare settings, where even a 2025 estimate still puts rare diseases at about 300 million people worldwide, so access and trust drive enrollment.
- Find patients faster
- Raise trial awareness
- Shape endpoints
- Support ultra-rare enrollment
Passage Bio’s Rare-Disease Network: Science, Supply, and Trial Support
Passage Bio, Inc. depends on the University of Pennsylvania Gene Therapy Program for vector science and translational research, Catalent Maryland, Inc. for AAV manufacturing, and specialist neurologists plus academic centers for ultra-rare trial execution. Patient groups also matter because rare diseases affect about 300 million people worldwide, while NIH supports 58 CTSA hubs that help with biomarker and follow-up work.
| Partner | Role | Key data |
|---|---|---|
| University of Pennsylvania | Gene therapy science | Core AAV platform support |
| Catalent Maryland, Inc. | Clinical AAV supply | External manufacturing capacity |
| NIH CTSA hubs | Trial support | 58 hubs |
What is included in the product
Detailed Word Document
A concise, real-company business model canvas for Passage Bio, Inc. tailored to its gene therapy strategy.
Customizable Excel Spreadsheet
Quickly maps Passage Bio’s strategy into a clear, editable snapshot for faster review and decisions.
Reference Sources
Provides a credible source trail for Passage Bio, Inc., helping decision-makers verify claims fast and trust the analysis.
Activities
Advance 6 pipeline programs
As of FY2025, Passage Bio’s key activity is advancing 6 CNS genetic therapy programs: PBGM01, PBFT02, PBKR03, PBML04, PBAL05, and PBCM06. These target GM1 gangliosidosis, FTD-GRN, Krabbe disease, MLD, ALS, and CMT2A, so the company’s work is centered on a focused rare-neurology pipeline.
Design AAV gene therapies
Passage Bio, Inc. designs AAV gene therapies by engineering viral vectors that deliver functional genes to the central nervous system. Its core platform work centers on AAVhu68 for PBGM01 and PBKR03, and AAV1 for PBFT02, making vector design the main technical activity behind its pipeline.
Run preclinical and clinical development
Passage Bio moves gene therapy assets from discovery into human studies through pharmacology, toxicology, dose selection, and clinical execution. In 2025, that work still centers on IND-enabling data and Phase 1/2 readouts, because regulators need clean safety and dosing evidence before any broader progression.
Manage CMC and clinical supply
In FY2025, Passage Bio, Inc. relied on Catalent Maryland for CMC development and supply while it produced investigational vector lots and kept clinical inventory moving. For gene therapy, CMC quality is make-or-break: each lot must clear identity, purity, and sterility checks before patients can receive it.
- Produce investigational vector lots
- Maintain clinical supply continuity
- Use Catalent Maryland support
- Protect CMC quality and release
Maintain collaborations and regulatory interactions
Passage Bio keeps its University of Pennsylvania collaboration and external trial partners aligned to move orphan-disease programs through clinic and scale-up. It also works with regulators on safety, manufacturing, and trial design, which is critical for rare-disease studies where patient counts are small and each protocol change can affect speed and risk.
- University of Pennsylvania collaboration supports pipeline work
- External trial partners help run studies
- Regulatory talks cover safety, manufacturing, design
Passage Bio Advances Six CNS Gene Therapy Programs in FY2025
As of FY2025, Passage Bio’s key activities were advancing six CNS gene therapy programs, running IND-enabling work and Phase 1/2 studies, and producing AAV vector lots for clinical supply. It also managed CMC work with Catalent Maryland and kept regulatory, toxicology, and trial partners aligned for rare-neurology development.
| FY2025 focus | Data |
|---|---|
| Programs | 6 |
| Vector platforms | AAVhu68, AAV1 |
| Clinical stage | Phase 1/2 |
| CMC partner | Catalent Maryland |
What You See Is What You Get
Business Model Canvas
This preview shows the actual Passage Bio, Inc. Business Model Canvas you’ll receive after purchase. It is not a sample or placeholder—what you see here is a real section of the final document. Once you buy, you’ll get the same file in full, with the same layout and content.
Resources
Proprietary AAVhu68 capsid
Passage Bio’s proprietary AAVhu68 capsid is the core CNS delivery engine behind PBGM01 and PBKR03. It is a key platform asset and a clear pipeline differentiator, since the same vector supports both lead programs and underpins the company’s gene delivery strategy.
AAV1 capsid program know-how
PBFT02 uses an AAV1 capsid to deliver GRN, showing Passage Bio, Inc. knows how to pick vectors for brain targeting. That know-how broadens the platform beyond one capsid, which can support faster follow-on programs and lower single-vector risk.
Pipeline of 6 investigational assets
Passage Bio, Inc. has six investigational programs in rare neurologic diseases, and that pipeline is the core of its key resources. Each asset adds clinical and regulatory optionality, while the company’s 2024 annual report showed $25.8 million in cash and equivalents at year-end, underscoring how tightly value depends on pipeline progress.
University of Pennsylvania collaboration
Passage Bio, Inc. relies on the University of Pennsylvania Gene Therapy Program as a core external resource for vector discovery and gene therapy know-how, giving it translational depth that is hard to build in-house. This collaboration sits behind Passage Bio, Inc.'s AAV-based platform and remains one of its most important scientific partnerships.
- Deepens vector discovery and translational development
- Supports AAV gene therapy platform work
- Anchors a key external R&D resource
Philadelphia headquarters and team
Passage Bio, Inc. was founded in 2017 and is based in Philadelphia, Pennsylvania, putting it inside a strong gene therapy hub with nearby talent, labs, and research links. Its Philadelphia headquarters, team, and facilities are core resources for running clinical and research work; by 2025/2026, that local operating base remains one of its main execution assets.
- Founded in 2017
- Headquarters: Philadelphia, Pennsylvania
- Access to Pennsylvania gene therapy ecosystem
- Team and facilities drive operations
Passage Bio’s AAV Edge Powers Its Rare Disease Pipeline
Passage Bio, Inc.’s key resources are its AAV platform, led by the proprietary AAVhu68 capsid and the AAV1-based PBFT02 program, plus six rare neurologic disease assets that keep pipeline value tied to CNS delivery know-how. Its University of Pennsylvania Gene Therapy Program link and Philadelphia base add scarce R&D talent, while year-end cash and equivalents were $25.8 million.
| Key resource | Why it matters |
|---|---|
| AAVhu68 | CNS delivery platform |
| PBFT02 AAV1 know-how | Broadens vector use |
| Six programs | Pipeline optionality |
Value Propositions
Gene therapies for CNS rare diseases
Passage Bio targets severe CNS rare diseases, focusing on underserved neurologic and neurodegenerative conditions where fewer than 10% of rare diseases have approved treatments. Its gene therapy pipeline aims at markets that still leave about 300 million people worldwide with limited options.
Root-cause gene replacement
Passage Bio, Inc. centers its value on root-cause gene replacement: PBGM01 for GLB1, PBFT02 for GRN, and PBKR03 for GALC. By delivering functional genes to replace the faulty one, the goal is to change disease biology at the source, not just ease symptoms.
Brain and peripheral tissue delivery
PBGM01 is built to reach both the brain and peripheral tissues, and PBKR03 is aimed at the brain plus surrounding tissues, which matters because systemic lysosomal diseases often need broad biodistribution, not just CNS exposure. In 2025, Passage Bio kept this delivery focus central as it targets disorders where one tissue alone is not enough.
Ultra-rare pediatric and neurodegenerative focus
Passage Bio, Inc. targets ultra-rare childhood diseases and later-onset neurodegeneration: infantile GM1 gangliosidosis and infantile Krabbe disease affect roughly 1 in 100,000 births each, while ALS and FTD-GRN address large unmet needs with no disease-modifying cure. This mix spans pediatrics to adults and sharpens its orphan-drug edge.
- Rare-disease focus supports high unmet need
- Programs span infant to adult patients
- Orphan scope can speed adoption
AAV platform across multiple programs
Passage Bio, Inc. uses one AAV platform across several programs, so it can reuse capsid design, CMC work, and clinical know-how. That kind of platform breadth can lower repeat work and support faster pipeline moves, which is key for a company that still reports no product revenue in its latest annual filing.
- Reuses one AAV science base
- Shares manufacturing and process know-how
- Speeds follow-on program work
- Supports pipeline efficiency and cost discipline
Passage Bio Targets Ultra-Rare CNS Diseases With Root-Cause Gene Therapy
Passage Bio’s value proposition is a root-cause AAV gene therapy platform for ultra-rare CNS diseases with no disease-modifying cures, led by PBGM01, PBFT02, and PBKR03. Its rare-disease focus targets markets where fewer than 10% of rare diseases have approved treatments and where GM1 gangliosidosis and Krabbe disease each affect about 1 in 100,000 births.
| Value driver | Key data |
|---|---|
| Pipeline focus | PBGM01, PBFT02, PBKR03 |
| Unmet need | <10% of rare diseases approved |
| Core markets | ~300M people with limited options |
Customer Relationships
Clinical trial participation
Passage Bio, Inc. depends on informed consent and protocol-driven enrollment for investigational studies, so the patient is the direct customer relationship in the clinical stage. Safety monitoring and follow-up are built into this link; in 2025, the company still had no product revenue and remained focused on advancing its gene therapy pipeline through clinical development.
Physician and investigator engagement
Specialist doctors and trial investigators are the main channel for finding eligible patients and delivering Passage Bio, Inc. therapies, so the company has to keep tight scientific contact with them. Their site-level feedback can change study operations and even endpoints, which matters in rare-disease trials where patient pools are small and each protocol choice has outsized impact.
Long-term patient monitoring
Passage Bio, Inc. must keep patients in long follow-up because gene therapy safety tracking can extend up to 15 years after dosing, per FDA guidance. That matters most in pediatric and CNS programs, where delayed effects and durable response data shape re-dosing, safety, and value. This long horizon also supports trust with families and trial sites.
Disease-community outreach
Passage Bio, Inc. depends on disease-community outreach because rare diseases affect about 300 million people worldwide across more than 7,000 conditions, so small patient groups need clear education on trial goals, site access, and family support. Strong communication with advocacy groups helps build awareness, guide navigation, and keep enrollment moving when each eligible patient matters.
- Rare-disease groups boost trial awareness
- Family education helps enrollment
- Small pools make outreach critical
Scientific exchange with centers
Passage Bio’s ties with academic centers and clinical sites are highly specialized: teams meet often to review patient data, discuss cases, and update trial protocols. In 2024, Passage Bio reported $15.8 million in cash and equivalents, underscoring how these expert-led relationships support a lean, research-heavy model rather than a broad sales network.
Frequent data review with centers
Case-by-case clinical discussion
Protocol updates drive execution
Passage Bio’s rare-disease trust model hinges on long-term patient follow-up
Passage Bio, Inc. keeps customer ties centered on rare-disease patients, family caregivers, and specialist investigators, with informed consent, safety follow-up, and protocol changes shaping the relationship. Because gene therapy follow-up can run 15 years under FDA guidance, trust and long-term contact matter more than volume.
In 2025, Passage Bio, Inc. still had no product revenue, so these relationships mainly support trial enrollment and data quality, not repeat sales. Rare-disease outreach and academic site feedback are the key links that keep studies moving.
| Metric | Value |
|---|---|
| 2025 product revenue | $0 |
| FDA follow-up horizon | Up to 15 years |
Channels
Academic clinical trial sites
Academic clinical trial sites are Passage Bio, Inc.'s main patient channel, because its investigational programs depend on research hospitals for screening, dosing, and follow-up. In 2025, Passage Bio still had no product revenue, so site quality directly drives enrollment speed and data quality.
Specialist neurologists and geneticists
Passage Bio, Inc. depends on specialist neurologists and geneticists because ultra-rare disorders have tiny pools of eligible patients: GM1 gangliosidosis is estimated at about 1 in 100,000 to 200,000 births, and these physicians are the main gatekeepers for diagnosis, referral, and trial enrollment. They also help coordinate confirmatory testing and care, which is key when patient access is so limited.
University research network
Passage Bio, Inc. uses its collaboration with the University of Pennsylvania as a scientific and clinical network that helps move gene therapy programs from lab work into patient studies, while also tapping specialist know-how across neurology, gene delivery, and translational research.
Company medical communications
Passage Bio uses company medical communications to push trial updates and program status to clinicians and investors through presentations, papers, and investor decks. In its latest filings, the Company reported no product revenue, so these updates are a key channel for signaling clinical progress and keeping stakeholders aligned.
Trial updates
Publications and presentations
Investor materials
Rare-disease community touchpoints
Patient organizations are key touchpoints in rare disease, where 300 million people worldwide live with 7,000+ conditions and about 95% still lack an approved treatment. For Passage Bio, Inc., these groups help families find trials, learn diagnostic paths, and connect fast when patient counts are tiny.
- Best reach point for ultra-rare patients
- Drives trial awareness and diagnosis
- Critical when each cohort is very small
Passage Bio’s ultra-rare reach runs through specialists and academic sites
Passage Bio, Inc. reaches ultra-rare patients mainly through academic trial sites, specialist neurologists, geneticists, and patient groups. With no product revenue in 2025, these channels are the core path to screening, referral, enrollment, and trial retention. A 2025 10-K showed the Company remained a clinical-stage gene therapy developer.
| Channel | Role | 2025 data |
|---|---|---|
| Academic sites | Enroll and follow patients | No product revenue |
| Specialists | Diagnose and refer | GM1 is 1 in 100,000-200,000 births |
Customer Segments
Infantile GM1 gangliosidosis
PBGM01 targets infantile GM1 gangliosidosis, a very rare lysosomal storage disorder with published incidence estimates of about 1 in 100,000 to 1 in 300,000 live births. The core customer segment is families facing early, severe neurodegeneration and the treating specialists who diagnose and manage this mostly pediatric disease.
FTD-GRN
PBFT02 targets adults with frontotemporal dementia linked to GRN mutations, a rare neurodegenerative segment that affects roughly 10,000 to 15,000 people in the United States. Neurology specialists, especially memory-disorder and movement-disorder clinics, are the key decision-makers and care hubs for this patient base.
Infantile Krabbe disease
PBKR03 targets infantile Krabbe disease, a rare early-onset leukodystrophy that often appears in the first 6 months of life and rapidly damages the CNS. The main users are pediatric neurologists and metabolic specialists; with U.S. newborn screening now covering more than 30 states for Krabbe disease, referral and diagnosis are concentrated in a small, specialist-led patient pool.
Metachromatic leukodystrophy
PBML04 is being developed for metachromatic leukodystrophy, a severe inherited white-matter disease that affects about 1 in 40,000 to 1 in 160,000 births. The customer segment is mainly pediatric patients and families, where diagnosis and early referral matter because treatment works best before major neurologic decline.
- Rare, high-unmet-need genetic disorder
- Early diagnosis drives treatment access
ALS and CMT2A
PBAL05 and PBCM06 expand Passage Bio, Inc. into ALS and Charcot-Marie-Tooth Type 2A, so the customer base now spans adult neurology and hereditary neuropathy as well as pediatric care. ALS affects about 5.0 people per 100,000 globally, while CMT impacts roughly 1 in 2,500 people, supporting a rare-disease market with high unmet need.
PBAL05/PBCM06: adult ALS and inherited neuropathy. One pipeline, two age groups.
- Adult neurology demand rises with ALS
- Hereditary neuropathy need is long-term
- Portfolio now spans pediatric and adult patients
Passage Bio Targets High-Need Ultra-Rare Neurology Markets
Passage Bio, Inc. serves ultra-rare pediatric and adult neurology segments: families and specialist clinics for GM1, GRN-FTD, Krabbe, and MLD, plus adult neurology and hereditary neuropathy for ALS and CMT2A. The pool is small but high-need, with diagnosis and referral concentrated in academic centers and newborn-screening networks.
| Segment | Key buyer | Need |
|---|---|---|
| Rare genetics | Specialists | Early treatment |
| Adult neurology | Memory clinics | Disease slowing |
Cost Structure
Research and discovery spend
Research and discovery spend is a core cost for Passage Bio, Inc. because it must keep funding vector design, assay development, and translational research to build and optimize new gene therapy assets. In a platform gene therapy model, this spend supports the pipeline before revenue, and in fiscal 2025 the company still carried R&D as a central operating cost tied to that asset-generation work.
Clinical trial expenses
Clinical trial expenses are a major cost driver for Passage Bio, Inc.: human studies need site fees, monitoring, data management, and patient support, and rare-disease programs often recruit from very small patient pools. That makes each added year of follow-up more expensive, with public rare-disease studies often running on cohorts of just dozens of patients.
Manufacturing and CMC
Manufacturing and CMC are a major cost driver for Passage Bio, Inc. because gene therapy needs vector production, analytical testing, batch release, cold-chain storage, and strict quality controls. Catalent support lowers the internal burden, but it still leaves Passage Bio, Inc. exposed to high per-batch CMC spend and scale-up risk.
Personnel and G&A
Passage Bio's personnel and G&A base is fixed-cost heavy: it needs scientific, clinical, regulatory, and corporate staff, while legal, finance, audit, and listing compliance keep public-company overhead high. That means headcount and back-office support stay expensive even when research spending moves up or down.
- Scientific, clinical, regulatory staff
- Legal, finance, public-company overhead
- Headcount is fixed operating cost
IP and collaboration costs
Passage Bio, Inc. has no product revenue and its IP costs sit in legal, patent, and contract spending tied to keeping vector and program rights protected. Collaboration duties with the University of Pennsylvania and vendors also add fixed fees, so these costs stay meaningful even while revenue was $0.
- Protect patents and licenses.
- Pay Penn and vendor obligations.
- Defend vector and program IP.
Passage Bio’s 2025 Costs Are All R&D, with Zero Revenue to Offset Them
Passage Bio, Inc. is still a pre-revenue gene therapy company, so its cost structure is dominated by R&D, clinical work, CMC, and public-company overhead in fiscal 2025. In 2025, revenue was $0, so every dollar of spending went to pipeline and platform work.
| FY2025 cost driver | Signal |
|---|---|
| Revenue | $0 |
| Main spend | R&D, trials, CMC |
| Overhead | Fixed SG&A |
That means Passage Bio, Inc. needs tight cash control because each program adds lab, patient, and manufacturing spend before any product sales arrive.
Revenue Streams
No approved product sales
Passage Bio, Inc. is still a development-stage biopharmaceutical company, so it has no approved CNS gene therapy and no product sales revenue base. In its most recent reported fiscal year, product revenue was $0, while the business continued to fund R&D and clinical work from cash on hand and financing.
Future gene therapy sales
If Passage Bio, Inc. wins approvals, future gene therapy sales could become the core long-term revenue stream, with rare-disease one-time therapies often priced in the $2 million to $3.5 million range, like Zolgensma at about $2.1 million and Hemgenix at $3.5 million. Today, Passage Bio, Inc. still has no commercial product revenue, so this line is tied to regulatory success and launch execution.
Collaboration payments
Collaboration payments can bring upfront cash, milestone fees, and service income from R&D deals, which is standard in gene therapy. Passage Bio’s Penn link and its manufacturing network fit this model, but its latest SEC filings show no collaboration revenue reported, so this stream is still more strategic than material.
Licensing and milestone income
Passage Bio, Inc. could monetize platform or program rights through licenses, with milestone payments linked to development, regulatory, or launch events. In fiscal 2025, the company reported no product revenue, so licensing and royalties would matter only if it signs a partner deal.
- Licenses can bring upfront cash.
- Milestones depend on key events.
- Royalties need partnered assets.
Non-dilutive funding
Passage Bio, Inc. has no product revenue in fiscal 2025, so non-dilutive funding matters for rare-disease programs. Grants and other external research money can extend preclinical and clinical work without issuing new shares or adding debt.
- Best fit when revenue is $0
- Supports preclinical and clinical work
- Limits dilution from equity raises
Passage Bio Remains Pre-Commercial, Funding Still Drives Cash
Passage Bio, Inc. had no product sales in fiscal 2025, so revenue streams remain pre-commercial and depend on future CNS gene therapy approvals. Near term, cash will still come mainly from equity financing and any partnership cash, not from sales.
| Stream | Fiscal 2025 |
|---|---|
| Product revenue | $0 |
| Collaboration revenue | $0 reported |
| External funding | Main cash source |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.